Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MER + bacillus calmette-guérin
- Development stage
- Discontinued
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
MER + bacillus calmette-guérin is a combination immunotherapy consisting of the methanol extraction residue (MER) derived from Bacillus Calmette-Guérin (BCG), a live attenuated strain of Mycobacterium bovis. This combination has been investigated as an adjuvant immunotherapeutic agent in cancer treatment, particularly for extensive non-small-cell lung cancer and advanced Hodgkin's disease. The mechanism involves immune system stimulation; BCG acts as a biologic response modifier by activating immune cells to attack tumor cells, while the MER component is thought to enhance or modulate this immune response. However, clinical studies have shown that adding MER to standard chemotherapy or maintenance regimens did not improve outcomes and was associated with significant toxicity and poor tolerability[1][2]. The use of this specific combination is investigational and not widely adopted in current practice.
- Other names
- methanol-extracted residue of Bacillus Calmette-GuérinMER/BCG
Beyond the preview
Go deeper on MER + bacillus calmette-guérin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MER + bacillus calmette-guérin.